PDL BioPharma, Inc. (NASDAQ:PDLI)

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.

PDL BioPharma, Inc. (NASDAQ:PDLI)’s Financial Overview

PDL BioPharma, Inc. (NASDAQ:PDLI) declined -4.58% yesterday to close its trading session at $2.29. The company has 1 year Price Target of $3.5. PDL BioPharma, Inc. has 52-Week high of $3.95 and 52-Week Low of $2.26. The stock touched its 52-Week High on Dec 17, 2015 and 52-Week Low on Nov 28, 2016. The stock traded with the volume of 6.02 Million shares yesterday. The firm shows the market capitalization of $379.13 Million.

PDL BioPharma, Inc. (NASDAQ:PDLI) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $0.11/share against the analyst consensus estimate of $0.08/share. The difference between the actual and expected EPS is $0.03 a share with a surprise factor of 37.5%.

The firm is trading with SMA20 of -26.94 Percent, SMA50 of -28.69 Percent and SMA200 of -28.5 percent. PDL BioPharma, Inc. has P/S value of 1.07 while its P/B value stands at 0.5. Similarly, the company has Return on Assets of 16.1 percent, Return on Equity of 23.9 percent and Return on Investment of 37.8 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 85.7 percent respectively.

Many brokerage firms are involved in issuing their ratings on PDL BioPharma, Inc. (NASDAQ:PDLI). On 20-Jan-11 RBC Capital Mkts Upgrade PDL BioPharma, Inc. Stock  to Outperform. Another firm also rated the stock on 10-Sep-10 where RBC Capital Mkts Initiated the stock to Sector Perform.

The Stock currently has Analyst’ mean Recommendation of 3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 2 analysts offering 12-month price forecasts for PDL BioPharma Inc have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +52.84% increase from the last price of 2.29.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Hanesbrands Inc. (NYSE:HBI)

Hanesbrands Inc. is a leading marketer of innerwear, outerwear and hosiery apparel under strong consumer brands, including Hanes, Champion, Playtex, Bali, Just My Size, barely there and Wonderbra. The company designs, manufactures, sources and sells T-shirts, bras, panties, men’s underwear, children’s underwear, socks, hosiery, casual wear and active wear. Hanesbrands Inc. is a world-class consumer goods company with more than a century of history and a portfolio of leading apparel essentials brands including Hanes, Champion, Playtex, Bali, L’eggs, Just My Size, Barely There and Wonderbra. Hanesbrands sells high-volume apparel essentials such as T-shirts, bras, panties, men’s underwear, kids’ underwear, socks, hosiery, casualwear and activewear.

Hanesbrands Inc. (NYSE:HBI)’s Financial Outlook

The 14 analysts offering 12-month price forecasts for HanesBrands Inc have a median target of 34.00, with a high estimate of 39.00 and a low estimate of 26.00. The median estimate represents a +44.87% increase from the last price of 23.47.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Hanesbrands Inc. has a Consensus Recommendation of 1.65. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -1.35% and closed its last trading session at $23.47. The company has the market capitalization of $8.87 Billion. The stock has 52-week high of $31.59 and 52-Week low of $23.25. The firm touched its 52-Week high on Dec 2, 2015 and 52-Week low on Feb 8, 2016. The company has volume of 6.01 Million shares. The company has a total of 377.95 Million shares outstanding.

Hanesbrands Inc. (NYSE:HBI) in the last quarter reported its actual EPS of $0.56/share where the analyst estimated EPS was $0.56/share. The difference between the actual and Estimated EPS is $0. This shows a surprise factor of 0 percent.

The company has YTD performance of -18.88 percent. Beta for Hanesbrands Inc. stands at 0.97 while its ATR (average true range) is 0.62. The company has Weekly Volatility of 2.03%% and Monthly Volatility of 2.35%%.

Hanesbrands Inc. has distance from 20-day Simple Moving Average (SMA20) of -4.46%, Distance from 50-Day Simple Moving Average of -5.59 percent and Distance from 200-Day Simple Moving Average of -11.23%.

The Company currently has ROA (Return on Assets) of 7.9 percent, Return on Equity (ROE) of 44.9 Percent and Return on Investment (ROI) of 14.2% with Gross margin of 37.6 percent and Operating & Profit margin of 12.4% and 8.6% respectively.